InnoCare Pharma Ltd is a CN-based company operating in Biotechnology industry. The company is headquartered in Beijing, Beijing and currently employs 1,146 full-time employees. The company went IPO on 2020-03-23. InnoCare Pharma Ltd is a China-based company mainly engaged in the research and development, production and commercialization of biopharmaceuticals. The firm focuses on areas with large unmet clinical needs, such as oncology and autoimmune diseases. The firm's primary product pipeline includes Orelabrutinib, Tafasitamab, ICP-490, ICP-B02, ICP-248, ICP-B05, ICP-332, ICP-488, ICP-192, ICP-723, ICP-033 and ICP-189, and others. Its products are mainly used to treat hematological tumors, solid tumors and autoimmune diseases. The firm is also developing products for the treatment of autoimmune diseases caused by abnormal B cell or T cell function. The firm mainly conducts its businesses in domestic and overseas markets.
Follow-Up Questions
InnoCare Pharma Ltd 的 CEO 是谁？
Dr. Jisong Cui 是 InnoCare Pharma Ltd 的 Executive Chairman of the Board，自 2015 加入公司。
INCPF 股票的价格表现如何？
INCPF 的当前价格为 $0，在上个交易日 decreased 了 0%。
InnoCare Pharma Ltd 的主要业务主题或行业是什么？
InnoCare Pharma Ltd 属于 Biotechnology 行业，该板块是 Health Care
